In Vitro Antiviral Susceptibilities of Isolates from Cytomegalovirus Retinitis Patients Receiving First‐ or Second‐Line Cidofovir Therapy: Relationship to Clinical Outcome

Citations Over TimeTop 12% of 1998 papers

Abstract

Blood culture isolates from patients receiving first- (peripheral retinitis) or second-line (relapsing retinitis) therapy with intravenous cidofovir were obtained from three clinical trials for in vitro antiviral susceptibility analyses. Isolates from 6 patients obtained after 14.3 weeks (mean) of first-line cidofovir therapy showed complete susceptibility to cidofovir, ganciclovir, and foscarnet. Isolates from 20 patients were obtained after 17.3 weeks (mean) of second-line cidofovir therapy. Ten showed complete susceptibility to all inhibitors, 3 showed low-level ganciclovir resistance (<6-fold) but were sensitive to cidofovir and foscarnet, and 7 showed moderately reduced susceptibility (<8-fold) to cidofovir and high-level resistance (8- to 23-fold) to ganciclovir in vitro. Four of these 7 isolates showed reduced susceptibility (4-fold) to foscarnet. Notably, there was no difference in time to retinitis progression in patients that were on cidofovir therapy when sensitive isolates were compared with those showing reduced susceptibility to cidofovir in vitro.

Related Papers

• → High-dose intravitreal ganciclovir and foscarnet for cytomegalovirus retinitis(2001)29 cited
• → Therapeutic Options for Resistant Cytomegalovirus Retinitis(1997)21 cited
• → Treatment of Clinically Resistant Cytomegalovirus Retinitis With Combined Intravitreal Injections of Ganciclovir and Foscarnet(1996)8 cited
• Intraocular therapy for cytomegalovirus retinitis.(1996)
• → Treatment of Clinically Resistant Cytomegalovirus Retinitis in AIDS Patients: Combination of Intravenous Ganciclovir and Intravitreal Foscarnet(1995)2 cited